The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

Correspondence to: Nancy A. Collop, MD, FCCP
Case Western Reserve University
Cleveland, OH

To the Editor:

In response to the letter of Drs. Quan and Redline regarding the American College of Chest Physicians (ACCP) product No. 6633, “SLEEP 2-Study Lessons in the Education and Evaluation of Polysomnography,” it is noted that question 5 in the “Sleep-Disordered Breathing Events” section contains a statement pertaining to oxygen desaturation as it was used to identify hypopneas by a study cited as a reference in the product.

The ACCP acknowledges the inaccuracy, and that the criterion in question was included as a means to make comparisons with the data of other studies.

Nancy A. Collop, MD, FCCP
Chair and Editor-in-Chief, SLEEP 2 (Study Lessons in Education and Evaluation of Polysomnography)
Baltimore, MD

The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

Correspondence to: Alfredo N. C. Santana, MD
Alfredo N. C. Santana, MD
Ronaldo A. Kairalla, PhD
Carlos R. R. Carvalho, PhD
University of São Paulo Medical School
Pulmonary Division and PSM-HC/PS-HU
São Paulo, Brazil

REFERENCE


Response

To the Editor:

We read the interesting article of Dr. Ksienski and colleagues1 that talks about cocaine, pulmonary edema, and siderophages. These cells are hemosiderin-laden alveolar macrophages characteristically found in BAL fluid or lung biopsy from patients with diffuse alveolar hemorrhage. Classically, diffuse alveolar hemorrhages are classified based on histologic appearance as capillaritis (Wegener granulomatosis, systemic lupus erythematosus, and propylthiouracil related), bland hemorrhage (coagulopathies, congestive heart failure, and rapamycin related), diffuse alveolar damage (ARDS and Crack cocaine inhalation), and miscellaneous conditions (lymphangioleiomyomatosis and pulmonary capillary hemangiomatosis).

However, we consider that macrophage activation syndrome should be included in the differential diagnosis of alveolar siderophages.2–5 Macrophage activation syndrome is a rare disease characterized by an immune dysregulation with excessive hemophagocytosis in lung/bone marrow/spleen (producing hemosiderin-laden macrophages), splenomegaly, bicytopenia, hypertriglyceridemia, hyperferritinemia > 500 μg/L, low natural killer-cell activity, increased plasma serum CD25, and fever.2 In addition, macrophage activation syndrome usually occurs in response to a triggering agent, such as tumors or infections (especially Epstein-Barr virus). Furthermore, macrophage activation syndrome may present with the triad of diffuse alveolar hemorrhage (lung infiltrates, a falling hemoglobin level, and worsening dyspnea).2–5 Therefore, chest physicians and pathologists should remember macrophage activation syndrome in patients with pulmonary infiltrates and falling hemoglobin levels and/or alveolar siderophages.

Alfredo N. C. Santana, MD
Ronaldo A. Kairalla, PhD
Carlos R. R. Carvalho, PhD
University of São Paulo Medical School
Pulmonary Division and PSM-HC/PS-HU
São Paulo, Brazil

REFERENCES